GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale ADA 2026 Scientific Sessions coverage
It is prescribed to patients with obesity (body mass index of 30 or more) and overweight (body mass index of 27 or more) with a weight-related condition like cardiovascular disease, high blood pressure, or type 2 diabetes
The neurochemical effects of GLP-1 medications on reward pathways appear to be dose-dependent and reversible
Can you take GLP-1s while breastfeeding
My hope in sharing this is to give a real-life glimpse of both the benefits and the bumps along the way
As consumers demand balance over intensity, winning brands will be those that pair functional performance with cleaner ingredients, multi-benefit appeal and relevance across ages, occasions and everyday life, shared Julia Mills, analyst at research firm Mintel, in the firms US Energy Drinks Market report